AMRN · Amarin Corp Plc\Uk
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. International in-market demand rose 59% year over year, U.S. IPE share increased to 48% and branded prescriptions rose 14%, while the completed restructuring cut operating expenses 38% excluding prior-year charges. The company guided to continued international growth, stable U.S. volumes, positive cash flow, and approximately 10% year-end cash growth, but Q2 net revenue fell 42%, gross margin contracted sharply, and COGS increased 22%.
- + Global partner in-market demand rose 59% year over year
- + U.S. IPE market share rose to 48% and branded prescriptions increased 14%
- + Completed cost savings reduced operating expenses 38% excluding restructuring charges
- + Full-year guidance calls for international growth, stable U.S. volumes, an improved cost profile, and positive cash flow
- − Q2 net revenue declined 42% year over year, primarily because the prior-year quarter included a $25 million upfront payment
- − U.S. product revenue declined 12% under continued generic competition and pricing pressure
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMRN
this stock
Amarin Corp Plc\Uk
|
$277.84M | -6.9% | +39.2% | — | 2.5% |
|
LLY
ELI LILLY & Co
|
$1.11T | +7.7% | +44.7% | 39.7 | 0.8% |
|
JNJ
Johnson & Johnson
|
$653.61B | +27.9% | +6.0% | 31.5 | 0.9% |
|
ABBV
AbbVie Inc.
|
$466.80B | +14.5% | +8.6% | 74.6 | 1.1% |
|
MRK
Merck & Co., Inc.
|
$367.07B | +38.0% | +1.3% | 119.0 | 1.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMRN | -5.3% | -6.1% | -12.0% | -6.3% | -6.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -4.6% | -6.3% | -24.2% | -5.8% | -18.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.